BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

St. Jude Medical (STJ) Receives FDA Warning Letter About One of Its Facilities


10/25/2012 9:13:20 AM

Minneapolis / St. Paul Business Journal by Katharine Grayson, Staff reporter

St. Jude Medical Inc. has received a warning letter from U.S. Food and Drug Administration related to operations at its manufacturing plant in Sylmar, Calif.

The Little Canada-based medical-device maker included the letter, portions of which were redacted, in a U.S. Securities and Exchange Commission filing. St. Jude CEO Daniel Starks warned investors last week that the company might receive a warning following an inspection of the facility, where it makes cardiac rhythm management products.

St. Jude (NYSE: STJ) said in the filing that the FDA did not identify a “specific issue regarding the clinical or field performance of any particular device.” The company also said it doesn’t expect costs associated with addressing the agency's concerns will have a “material impact” on its financial results.

The FDA's letter had 11 “observations,” including several related to “verification testing,” canine testing and the company's corrective and preventive actions policies.

St. Jude said it will respond to the FDA’s letter no later than Nov. 7.



Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES